Monitoring and switching of first-line antiretroviral therapy in adult treatment cohorts in sub-Saharan Africa: Collaborative analysis

The Lancet HIV

Volumn 2, Issue 7, 2015, Pages e271-e278

  Haas, Andreas D ^a   Keiser, Olivia ^a   Balestre, Eric ^b   Brown, Steve ^c   Bissagnene, Emmanuel ^d,aj   Chimbetete, Cleophas ^e   Dabis, François ^b,aj   Davies, Mary Ann ^f   Hoffmann, Christopher J ^g,h   Oyaro, Patrick ⁱ   Parkes Ratanshi, Rosalind ^j   Reynolds, Steven J ^k,l,m   Sikazwe, Izukanji ⁿ   Wools Kaloustian, Kara ^c   Zannou, D Marcel ^o,p,aq   Wandeler, Gilles ^a   Egger, Matthias ^a,f   Boulle, Andrew ^f   Campbell, Lucy ^f   Cornell, Morna ^f   Johnson, Leigh ^f   Maxwell, Nicola ^f   Myer, Landon ^f   Schomaker, Michael ^f   Porter, Mireille ^f   Nalugoda, Fred ^k   Chi, Benjamin ⁿ   Tanser, Frank ^q   Hoffimann, Christopher ^h   Naniche, Denise ^r   Wood, Robin ^s   Stinson, Kathryn ^t   Fatti, Geoffirey ^u   Phiri, Sam ^v   Giddy, Janet ^w   Malisita, Kennedy ^x   Eley, Brian ^f   Hobbins, Michael ^y   Kamenova, Kamelia ^z   Faturiyele, Olatunbosun ^aa   Fox, Matthew ^ab   Prozesky, Hans ^ac   Technau, Karl ^ad   Sawry, Shobna ^ae   Bohlius, Julia ^a   Blaser, Nello ^a   Estill, Janne ^a   Salazar Vizcaya, Luisa ^a   Haas, Andreas ^a   Ballif, Marie ^a   Rohner, Eliane ^a   Wyss, Natascha ^a   Baranczuk, Zofia ^a   Goodwin, Kelly ^a   Ha, Cam ^a   Ostinelli, Dao ^a   Ayaya, Samuel ^af   Diero, Lameck ^af   Sang, Edwin ^af   Rotich, Elyne ^af   Bukusi, Elizabeth ^ag   Somi, Geoffirey R ^ah   Lyamuya, Rita ^ai   Lugina, Edward ^aj   Urassa, Mark ^ak   Mkwasa, Denna Michael ^ak   Ngonyani, Kapella ^ak   Kambugu, Andrew ^al   Philippa Easterbrook, ^am   Achieng Kariuki, Marion ^am   Ssali, John ^an   Bwana, Mwebesa Bosco ^ao   Muyindike, Winnie ^ao   Yiannoutsos, Constantin T ^ap   Musick, Beverly S ^ap   Kuhn, Yee H ^ap   Drabo, Joseph ^ar   Sawadogo, Adrien Bruno ^as   Messou, Eugène ^at   Bosse, Clarisse Amani ^au   Chenal, Henri ^av   Minga, Albert ^aw   KoffiTanon, Aristophane ^d   Koule, Serge Olivier ^d   Wejse, Christian ^ax   Leuenberger, David ^ay   Hebelamou, Jean ^ay   Maïga, Moussa Y ^az   Traore, Hamar Alassane ^ba   Minta, Daouda ^ba   Kwaghe, Mali Vivian ^bb   Igbinoba, Festus ^bc   Benson, Okwara ^bd   Adebamowo, Clément ^bd   Seydi, Moussa ^be   Patassi, Akessiwe ^bf   Arrivé, Elise ^aj   de Rekeneire, Nathalie ^aj   Jaquet, Antoine ^aj   Leroy, Valériane ^aj   Lewden, Charlotte ^aj   Sasco, Annie ^aj   Coffie, Patrick ^aj   Ekouevi, Didier ^aj   Charurat, Man ^bg   more..

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d CENTRE HOSPITALIER UNIVERSITAIRE DE TREICHVILLE   (Côte d’Ivoire)

^e Newlands Clinic   (Zimbabwe)

^f UNIVERSITY OF CAPE TOWN   (South Africa)

^g JOHNS HOPKINS UNIVERSITY   (United States)

^h AURUM INSTITUTE   (South Africa)

ⁱ KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^j MULAGO HOSPITAL   (Uganda)

^k RAKAI HEALTH SCIENCES PROGRAM   (Uganda)

^l NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^m JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁿ CENTRE FOR INFECTIOUS DISEASE RESEARCH IN ZAMBIA   (Zambia)

^o Faculté des Sciences de la Santé de l'Université d'Abomey Calavi   (Benin)

^p Centre National Hospitalier Universitaire Hubert K Maga   (Benin)

^q UNIVERSITY OF KWAZULU NATAL   (South Africa)

^r Manhiça Health Research Center   (Mozambique)

^s Institute of Infectious Disease and Molecular Medicine   (South Africa)

^t MÉDECINS SANS FRONTIÈRES   (Switzerland)

^u Kheth'Impilo Programme   (South Africa)

^v LIGHTHOUSE TRUST   (Malawi)

^w MCCORD HOSPITAL   (South Africa)

^x QUEEN ELIZABETH CENTRAL HOSPITAL   (Malawi)

^y SolidarMed SMART Programme   (Mozambique)

^z Themba Lethu Clinic   (Zimbabwe)

^aa SolidarMed SMART Programme   (Lesotho)

^ab Tygerberg Academic Hospital   (South Africa)

^ac STELLENBOSCH UNIVERSITY   (South Africa)

^ad UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^ae UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^af ACADEMIC MODEL PROVIDING ACCESS TO HEALTHCARE AMPATH   (Kenya)

^ag Medical Research Institute   (Kenya)

^ah National AIDS Control Program   (Tanzania)

^ai Morogoro Regional Hospital   (Tanzania)

^aj Ocean Road Cancer Institute ^*  (Côte d’Ivoire)

^ak NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (Tanzania)

^al Tumbi Regional Hospital   (Tanzania)

^am MAKERERE UNIVERSITY   (Uganda)

^an Masaka Regional Referral Hospital   (Uganda)

^ao MBARARA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Uganda)

^ap INDIANA UNIVERSITY   (United States)

^aq CNHU Hubert K Maga   (Benin)

^ar Service d'Urologie   (Burkina Faso)

^as CHU Sanou Souro   (Burkina Faso)

^at ACONDA CePReF   (Côte d’Ivoire)

^au MTCT Plus Programme   (Côte d’Ivoire)

^av CIRBA   (Côte d’Ivoire)

^aw CMSDS CNTS   (Côte d’Ivoire)

^ax BANDIM HEALTH PROJECT   (Guinea-Bissau)

^ay Centre Medical Macenta   (Guinea)

^az Gabriel Toure Hospital   (Mali)

^ba Point G Hospital   (Mali)

^bb UATH   (Nigeria)

^bc NATIONAL HOSPITAL   (Nigeria)

^bd UBTH   (Nigeria)

^be Centre Hospitalier Universitaire Dakar   (Senegal)

^bf UNIVERSITÉ DE LOMÉ   (Togo)

^bg UMB IHV   (Nigeria)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; NEVIRAPINE; STAVUDINE; TENOFOVIR; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; AFRICA SOUTH OF THE SAHARA; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; DRUG MONITORING; DRUG SUBSTITUTION; FEMALE; FUNDING; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; TREATMENT FAILURE; VIRUS LOAD; DRUG EFFECTS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; STATISTICS AND NUMERICAL DATA;

ADULT; AFRICA SOUTH OF THE SAHARA; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DRUG MONITORING; DRUG SUBSTITUTION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT FAILURE; VIRAL LOAD;

EID: 84947041939     PISSN: None     EISSN: 23523018     Source Type: Journal    
DOI: 10.1016/S2352-3018(15)00087-9     Document Type: Article

References (30)

1. WHO. HIV/AIDS: data and statistics. 2015. http://www.who.int/ hiv/data/en/ (accessed April 8, 2015).
2. UNAIDS. 90-90-90: an ambitious treatment target to help end the AIDS epidemic. October, 2014. http://www.unaids.org/sites/default/ fi les/media_asset/90-90-90_en_0.pdf (accessed April 5, 2015).
3. Harries AD, Zachariah R, van Oosterhout JJ, et al. Diagnosis and management of antiretroviral-therapy failure in resource-limited settings in sub-Saharan Africa: challenges and perspectives. Lancet Infect Dis 2010; 10: 60-65.
4. Fox MP, Cutsem GV, Giddy J, et al. Rates and predictors of failure of first-line antiretroviral therapy and switch to second-line ART in South Africa. J Acquir Immune Defic Syndr 2012; 60: 428-37.
5. Keiser O, Tweya H, Braitstein P, et al. Mortality after failure of antiretroviral therapy in sub-Saharan Africa. Trop Med Int Health 2010; 15: 251-58.
6. Clinton Health Access Initiative. ARV ceiling price list. August, 2013. http://www.clintonhealthaccess.org/news-andinformation/ ARV-Ceiling-Price-List-May-2013 (accessed July 29, 2014).
7. Keiser O, Orrell C, Egger M, et al. Public-health and individual approaches to antiretroviral therapy: township South Africa and Switzerland compared. PLoS Med 2008; 5: e148.
8. WHO. Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants: recommendations for a public health approach. Geneva: World Health Organization, 2010.
9. Keiser O, MacPhail P, Boulle A, et al. Accuracy of WHO CD4 cell count criteria for virological failure of antiretroviral therapy. Trop Med Int Health 2009; 14: 1220-25.
10. Mee P, Fielding KL, Charalambous S, Churchyard GJ, Grant AD. Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa. AIDS 2008; 22: 1971-77.
11. Reynolds SJ, Nakigozi G, Newell K, et al. Failure of immunologic criteria to appropriately identify antiretroviral treatment failure in Uganda. AIDS 2009; 23: 697-700.
12. Sigaloff KC, Hamers RL, Wallis CL, et al. Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations: two arguments for viral load monitoring in Africa. J Acquir Immune Defic Syndr 2011; 58: 23-31.
13. Keiser O, Tweya H, Boulle A, et al. Switching to second-line antiretroviral therapy in resource-limited settings: comparison of programmes with and without viral load monitoring. AIDS 2009; 23: 1867-74.
14. Egger M, Ekouevi DK, Williams C, et al. Cohort profi le: the international epidemiological databases to evaluate AIDS (IeDEA) in sub-Saharan Africa. Int J Epidemiol 2012; 41: 1256-64.
15. Department of Health (Republic of South Africa). The South African antiretroviral treatment guidelines 2013. March 24, 2013. http://www.sahivsoc.org/upload/documents/2013%20ART%20 Treatment%20Guidelines%20Final%2025%20March%202013%20 corrected.pdf (accessed Nov 19, 2014).
16. WHO. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach-2006 revision. http://www.who.int/hiv/pub/guidelines/ artadultguidelines.pdf (accessed June 3, 2015).
17. WHO. WHO case defi nitions of HIV for surveillance and revised clinical staging and immunological classifi cation of HIV-related disease in adults and children. 2007. http://www.who.int/hiv/pub/ guidelines/HIVstaging150307.pdf (accessed June 3, 2015).
18. Gutierrez RG. Parametric frailty and shared frailty survival models. Stata J 2002; 2: 22-44.
19. Simon R, Makuch RW. A non-parametric graphical representation of the relationship between survival and the occurrence of an event: application to responder versus non-responder bias. Stat Med 1984; 3: 35-44.
20. WHO. March 2014 supplement to the 2013 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection-recommendations for a public health approach. Geneva: World Health Organization, 2014.
21. Lynen L, An S, Koole O, et al. An algorithm to optimize viral load testing in HIV-positive patients with suspected first-line antiretroviral therapy failure in Cambodia. J Acquir Immune Defic Syndr 2009; 52: 40-48.
22. Laurent C, Kouanfack C, Laborde-Balen G, et al. for the Stratall ANRS 12110/ESTHER study group. Monitoring of HIV viral loads, CD4 cell counts, and clinical assessments versus clinical monitoring alone for antiretroviral therapy in rural district hospitals in Cameroon (Stratall ANRS 12110/ESTHER): a randomised non-inferiority trial. Lancet Infect Dis 2011; 11: 825-33.
23. Orrell C, Harling G, Lawn SD, et al. Conservation of first-line antiretroviral treatment regimen where therapeutic options are limited. Antivir Ther 2007; 12: 83-88.
24. Landier J, Akonde A, Pizzocolo C, et al. Switch to second-line ART in West African routine care: incidence and reasons for switching. AIDS Care 2011; 23: 75-78.
25. Auld AF, Mbofana F, Shiraishi RW, et al. Four-year treatment outcomes of adult patients enrolled in Mozambique's rapidly expanding antiretroviral therapy program. PLoS One 2011; 6: e18453.
26. Palombi L, Marazzi MC, Guidotti G, et al. and DREAM Program. Incidence and predictors of death, retention, and switch to second-line regimens in antiretroviral-treated patients in sub-Saharan African sites with comprehensive monitoring availability. Clin Infect Dis 2009; 48: 115-22.
27. Mugyenyi P, Walker AS, Hakim J, et al. and the DART trial team. Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. Lancet 2010; 375: 123-31.
28. Jourdain G, Le Coeur S, Ngo-Giang-Huong N, et al. Switching HIV treatment in adults based on CD4 count versus viral load monitoring: a randomized, non-inferiority trial in Thailand. PLoS Med 2013; 10: e1001494.
29. Estill J, Salazar-Vizcaya L, Blaser N, Egger M, Keiser O. The cost-eff ectiveness of monitoring strategies for antiretroviral therapy of HIV infected patients in resource-limited settings: software tool. PLoS One 2015; 10: e0119299.
30. Estill J, Egger M, Blaser N, et al. Cost-eff ectiveness of point-of-care viral load monitoring of ART in resource-limited settings: mathematical modelling study. AIDS 2013; 27: 1483-92.